

Table of Content

CONTENT	Page No.
<i>Certificate</i>	i
<i>Acknowledgements</i>	ii-iv
<i>Abstract</i>	v-viii
<i>List of tables</i>	ix-x
<i>List of figures</i>	xi-xv
<i>List of abbreviations and symbols</i>	xvi-xxi
Chapter 1 - Introduction	1-32
1.0 Skin	1
1.1. Psoriasis	3
1.2. Pathogenesis of psoriasis	5
1.3. Therapies to treat psoriasis	8
1.4. Apremilast: A PDE4 inhibitor for the treatment of psoriasis	11
1.5. Topical drug delivery systems for the treatment of psoriasis	15
1.6. Lipid nanocarriers	19
1.7 Quality by design approach for formulation development	22
1.8. Current status of research on topical delivery of Apremilast	23
1.9 Gaps in the current research	24
Chapter 2 - Analytical method development	33-48
2.0 Introduction	33
2.1. Analytical method development of Apremilast	33
2.2. Materials, reagents, and chemicals	33
2.3. Stock, standard preparation and buffer preparation	34
2.4. Chromatographic conditions	34
2.5. Method validation	35
2.6. Results and discussion	37
2.7. Conclusion	46
Chapter 3 – Solid lipid nanoparticles	49-103
3.0 Introduction	49
3.1. Materials	50

3.2.Methods	50
3.3.Results and discussion	63
3.4.Conclusion	98
Chapter 4 – Nanostructured Lipid carriers	104-139
4.0 Introduction	104
4.1. Materials	104
4.2.Methods	105
4.3.Results and discussion	107
4.4.Conclusion	135
Chapter 5 – Lyotropic liquid crystal nanoparticles	140-179
5.0 Introduction	140
5.1. Materials	140
5.2.Methods	141
5.3.Results and discussion	144
5.4.Conclusion	175
Summary and Conclusion	180-184